SEC Tracker
Get the app

SI-BONE SIBN

SI-BONE Q1 FY25: revenue $47.3M, up 25%; diluted EPS −$0.15

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers SI-BONE reported for Q1 FY25, the quarter ended Mar 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$47.3M+25% from $37.9M in Q1 FY2410-Q income statement, on EDGAR
  2. Net income−$6.5MAgainst −$10.9M in Q1 FY2410-Q income statement, on EDGAR
  3. Diluted EPS−$0.15Against −$0.27 in Q1 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$41.2M+29% from $32.0M in Q1 FY2410-Q balance sheet, on EDGAR
  5. Cash from operations−$4.9MAgainst −$7.6M in Q1 FY2410-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when SI-BONE files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Biolife Solutions BLFS public float $845M, Jun 30, 2025
  2. Embecta EMBC public float $732M, Mar 31, 2025, over 18 months old
  3. Mimedx Group MDXG public float $719M, Jun 30, 2025
  4. Heartflow HTFL
  5. Integra Lifesciences Holdings IART public float $925M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.